The relationship between gut and skeleton is increasingly recognized as part of the integrated physiology of the whole organism. The incretin hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestine in response to nutrient intake and exhibit several physiological functions including regulation of islet hormone secretion and glucose levels. A number of GLP-1 receptor agonists (GLP-1RAs) are currently used in treatment of type 2 diabetes and obesity. However, GIP and GLP-1 cognate receptors are widely expressed suggesting that incretin hormones mediate effects beyond control of glucose homeostasis, and reports on associations between incretin hormones and bone metabolism have emerged. The aim of this MiniReview was to provide an overview of current knowledge regarding the in vivo and in vitro effects of GIP and GLP-1 on bone metabolism. We identified a total of 30 pre-clinical and clinical investigations of the effects of GIP, GLP-1 and GLP-1RAs on bone turnover markers, bone mineral density (BMD), bone microarchitecture and fracture risk. Studies conducted in cell cultures and rodents demonstrated that GIP and GLP-1 play a role in regulating skeletal homeostasis, with preclinical data suggesting that GIP inhibits bone resorption whereas GLP-1 may promote bone formation and enhance bone material properties. These effects are not corroborated by clinical studies. While there is evidence of effects of GIP and GLP-1 on bone metabolism in pre-clinical investigations, clinical trials are needed to clarify whether similar effects are present and clinically relevant in humans.
Bone remodelling is the regenerative mechanism that maintains the skeletal health and biomechanical competence through resorption of bone by osteoclasts and formation of new bone by osteoblasts. These processes are highly co-ordinated and under the influence of several hormonal factors [1] .
Incretin hormones encompass a group of hormones characterized by their ability to enhance insulin secretion in response to intake of nutrients, such as glucose and fat. The most important incretin hormones are gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [2] . Both of these hormones interact with cognate receptors, which are widely expressed in human tissues: the GIP receptor (GIPR) is expressed in pancreas, central nervous system, thyroid as well as adipose tissue [3] , and the GLP-1 receptor (GLP-1R) is expressed in the kidney, stomach, duodenum, central nervous system and pancreas [4] . Both the GIP and the GLP-1 receptors are 7-transmembrane proteins, and activation of these receptors by binding of either GIP or GLP-1 increases intracellular levels of cyclic adenosine monophosphate (cAMP) and Ca 2+ [5] .
Gastric inhibitory polypeptide and GLP-1 are secreted from enteroendocrine cells of the small intestine. Once secreted, GLP-1 binds to the GLP-1 receptors expressed on pancreatic b-cells, leading to a glucose-dependent insulin secretion but the effect is short-lived as GLP-1 is quickly degraded by the dipeptidyl peptidase-4 (DPP-4) enzyme, which is expressed on the surface of several cell types [2] . Observations of lower postprandial levels of GLP-1 in patients with type 2 diabetes have led to the development of DPP-4 inhibitors and GLP-1 receptor agonists (GLP1RAs) resistant to enzymatic degradation by DPP-4, and these drugs are currently widely used for the treatment of type 2 diabetes due to their glucose-lowering properties [2] . GLP-1RAs vary in several ways including their degree of homology with native human GLP-1 and pharmacokinetics. For example, compared to exendin-4, a naturally occurring peptide resistant to degradation by DPP-4, liraglutide, which is a GLP-1RA marketed for the treatment of type 2 diabetes, has a substantially higher degree of homology to native human GLP-1 (97% versus 53%) and a longer half-life (12 hr versus 2.4 hr) [6, 7] .
Unlike GLP-1, there is limited information regarding the physiological functions of GIP. Gastric inhibitory polypeptide stabilizes blood glucose levels by enhancing glucose-stimulated insulin secretion and promoting glucagon secretion at low Author for correspondence: Morten S. S. Hansen, Department of Endocrinology and Metabolism, OUH, Sdr. Boulevard 29, DK-6000 Odense C, Denmark (e-mail morten.steen.hansen@rsyd.dk).
glucose levels. Plasma levels of GIP are normal or increased in type 2 diabetes, and the secretion of GIP in response to an oral glucose tolerance test (OGTT) or a meal test in patients with type 2 diabetes is not different from healthy controls [3] .
The role of the skeleton in regulating overall energy metabolism is increasingly recognized and thought to be mediated by interaction between insulin and bone secreted 'metabolic hormones', for example osteocalcin [8] . Investigations of the effects of incretin hormones on bone metabolism have emerged, providing support of an integration of nutrient intake and bone metabolism [9] . Thus, the aim of this present MiniReview was to investigate our current knowledge regarding the effects of GIP, GLP-1 and GLP-1RAs on bone turnover and bone cell metabolism in animals and humans. In order to focus on the explicit effects of incretin hormones, DPP-4 inhibitors were not included in this review.
Materials and Methods
On 15 October 2016, we searched the databases PubMed, DARE and MEDLINE and used PubMatrix to crosscheck our search results using the following control words: 'GLP-1', 'GIP', 'Glucagon Like Peptide-1', 'Exenatide', 'Lixisenatide', 'Albiglutide', 'Liraglutide', 'Dulaglutide', and 'Semaglutide' together with the one of the next search words: 'Bone', 'Fracture', 'Osteoblast' and 'Osteoclast'. Eighty-nine articles were identified and screened independently by two authors. Articles in English language that reported the expression of incretin hormone receptors in bone cells or effects of GIP, GLP-1 or GLP1RAs on bone metabolism were included whereas reviews were excluded. A total of 21 pre-clinical studies (table 1), and nine clinical  studies (table 2) were included.
Results
Incretin hormones and bone cells.
GIP. Gastric inhibitory polypeptide receptors have been reported to be present in human and rodent osteoblastic cell lines that mirror different stages of osteoblast differentiation, including MG63, Saos-2 and ROS 17/2.8 osteosarcoma cell lines [10, 11] , TE-85 cells [11] , murine MC3T3-E1 [12] as well as primary murine osteoblasts and human osteoblasts [10] . The expression of GIPR has been reported to increase with osteoblastic cell maturity [11] . Furthermore, it has been shown that GIPR expression is glucose dependent in MC3T3-E1 osteoblastic murine cells [12] . However, similar effects have not been reported in human bone cell lines or primary cells.
Gastric inhibitory polypeptide receptor signalling in osteoblastic cells is associated with increased intracellular cAMP concentration and increased cell viability, collagen type 1 expression and alkaline phosphatase activity [10, 11] . Furthermore, GIP has been reported to inhibit osteoblastic cell apoptosis [13, 14] , bone marrow stem cell apoptosis [14] and osteoclastic cell activity in a dose-dependent manner in vitro, and GIP decreases both PTH and receptor activator of nuclear factor jb ligand (RANKL)-induced osteoclastic bone resorption, suggesting that GIP has a direct and inhibitory effect on osteoclasts [15] , indicating that GIP may promote bone formation and impede bone resorption.
GLP-1 -animals. Several investigators have assessed the effect of GLP-1 on animal bone cells, but the results are inconsistent.
Expressions of GLP-1Rs have been reported in murine osteoblasts, osteocytes and osteoclasts [12, 16, 17] , and studies have shown glucose-dependent expression of GLP-1R in osteoblastic cells during bone morphogenetic protein (BMP)-2-induced differentiation [12] . Furthermore, binding of GLP-1 to murine osteoblastic MC3T3-EI cells has been reported [18] . By contrast, GLP-1R expression was not detected in a number of other investigations of bone cells including murine MC3T3-E1 osteoblastic cells [18] , primary osteoblasts [19, 20] and osteoclasts [19] . Although the GLP-1R was not identified, treatment of osteoblastic MC3T3-E1 cells with GLP-1 induced hydrolysis of glycosylphosphatidylinositols (GPI) and increased phosphatidylinositol-3 kinase and mitogen-activated protein kinase (MAPK) activity, suggesting that GLP-1 influences osteoblast differentiation and activity through an unknown GPI-coupled receptor [18] . Furthermore, high doses of GLP-1 reduced the expression of genes involved in the development of osteoblasts such as the runt-related transcription factor 2 and major genes of the Wnt pathway, had no effect on mRNA levels of the RANKL decoy receptor osteoprotegerin but increased the expression of osteocalcin, which is a marker of late osteoblast maturation, suggesting that GLP-1 may promote the activity of mature osteoblasts rather than osteoblast differentiation. Additionally, it has also been reported that GLP-1 has no effect on intracellular cAMP levels [18, 20] or osteoblastic apoptosis (Saos-2 cell lines) or osteoclast differentiation and activity in vitro [20] .
GLP-1 -humans. GLP-1R expression has been reported in human osteoblastic cell lines but may depend on level of osteoblast development as the GLP-1R was expressed in all except the most developed human cell lines (MG63 and TE-85 but not Saos-2) [11] . GLP-1Rs were expressed in human bone marrow stem cells and adipose-derived stem cells retrieved from subcutaneous fat tissue [21, 22] . Additionally, GLP-1R expression was augmented during in vitro osteoblastic differentiation of adipose-derived stem cells [22] . Correspondingly, treatment of osteoblastic cell lines (MG63 and TE-85) with GLP-1 (7-36 amide) increased the viability but reduced the secretion of bone formation marker procollagen type 1 amino-terminal propeptides (P1NP), but not of alkaline phosphatase, which also reflects bone formation [11] . GLP-1 treatment of human bone marrow stem cells caused an increase in cell proliferation, decreased apoptosis and inhibited adipocyte differentiation by decreasing the expression of the peroxisome proliferator-activated receptor c (PPARc) [21] . Furthermore, GLP-1 treatment of adipose-derived stem cells stimulated osteoblast differentiation and decreased adipogenic differentiation in a dose-dependent manner [23] .
In vivo and ex vivo animal studies -GIP. Total and femoral BMD assessed by dual-energy X-ray absorptiometry (DXA) were lower in 4-week-old GIPR À/À mice, and total BMD GIPR expressed in all cell lines with highest levels in Saos-2 and lowest levels in MG-63 GIP increased alkaline phosphatase and P1NP production in Saos-2 and decreased P1NP secretion by TE-85 cells GIP had no effect on osteocalcin secretion Aoyama [12] Murine osteoblast-like cell (MC3T3-E1)
GIPR expressed in murine MC3T3-E1
Tsukiyama [13] Murine osteoclasts GIP (100 µM) No effect of GIP on osteoclast activity Berlier [14] Human [20] Murine primary osteoblasts and human osteoblast-like cells (Saos-2)
GLP-1 (10 lM for differentiation and 100 lM for osteoclast activity studies)
GLP-1R was not expressed in murine osteoblasts GLP-1 had no effect on apoptosis of osteoblastlike cells. GLP-1 without effect on osteoclast resorption activity Pereira [16] Murine GIP (1 µM for expression and 1-100 nM in apoptosis studies)
GIPR indicated but not confirmed GIP protected osteoblast-like cells from apoptosis in a dose-dependent manner Sanz [21] Human mesenchymal stem cells GLP-1 (10 nM) GLP-1R expressed in human mesenchymal stem cells GLP-1 promoted differentiation and decreased apoptosis of human mesenchymal stem cells GLP-1 inhibited adipocyte differentiation, partly through decreasing PPARc Jeon [22] Human adipose-derived stem cells GLP-1R expressed in human adipose-derived stem cells Lee [23] Human adipose-derived stem cells supporting that inactivation of the GIP and its receptor influence bone metabolism [24] . Furthermore, microcomputed tomography (micro-CT) scans showed smaller bones with impaired microarchitecture and abnormal trabecular structure in 5-month-old GIPR À/À mice [24] . The GIPR knockout was obtained by targeted disruptions of exon 4 and 5 in the GIPR gene, and only female mice were used. Interestingly, when using another GIPR knockout method targeting exons 6-10, increased trabecular number and volume as assessed by micro-CT were reported in another study, which comprised of 16-week-old GIPR À/À and wild-type (WT) mice [25] .
Measurements of bone turnover markers revealed higher urinary deoxypyridinoline, a marker for bone resorption, as well as lower levels of bone formation markers (osteocalcin and alkaline phosphatase) in 8-week-old GIPR À/À mice than in matched WT mice [13] . In contrast, no change in serum deoxypyridinoline was observed in 5-month-old GIPR [24] . Consistent with the increased urinary elimination of deoxypyridinoline, GIPR À/À mice (8 weeks old) had increased number of osteoclasts assessed by histochemical analyses and lower bone formation rate assessed by bone histomorphometry [13] . By contrast, fewer osteoclasts, unaffected number of osteoblasts and increased bone formation rate as assessed by histomorphometry and increased runt-related transcription factor 2, osteocalcin and collagen-I gene expressions and decreased RANKL gene expression were observed in GIPR À/ À -cultured osteoblastic cells [25] . In the same study, biomechanical tests revealed weaker bone in GIPR À/À mice suggesting that bone matrix deteriorates in the absence of GIP signalling [25] . Impairment of bone strength was also observed in 5-month-old GIPR À/À mice, presumably due to increased bone resorption and impaired bone formation [24] . On the other hand, transgenic mice overexpressing GIP exhibited increased bone formation and decreased bone resorption markers (osteocalcin and deoxypyridinoline, respectively) as well as fewer osteoclasts and increased bone mass [26] . Consistent with the proposed antiresorptive effect of GIP, 6 weeks of daily injection of GIP attenuated bone loss in ovariectomized 8-week-old mice [27] . Furthermore, while treatment of 8-week-old streptozotocin-induced diabetic mice with daily GIP injection for a total of 21 days failed to improve the deleterious effects of diabetes on cortical bone mineral density, thickness and strength, nanoindentation tests showed that GIP increased bone mechanical properties and collagen integrity in mice [28] .
In vivo and ex vivo animal studies -GLP-1. The number of osteoclasts in the tibia and bone resorption but not bone formation was higher in 6-week-old GLP-1R À/À mice than in WT mice [20] . Additionally, cortical but not trabecular bone mass of the tibia and spine as well as bone strength was lower in 10-week-old GLP-1R À/À mice compared to WT mice [20] .
In agreement with these results, bone mineral content, bone diameter, cortical thickness and bone material properties such as work to fracture and yield strength were decreased in 16-week-old GLP-1R À/À mice [19] .
Three days of continuous infusion of human GLP-1 in 10-week-old healthy, D-fructose-induced insulin-resistant and streptozotocin-induced diabetic Wistar rats revealed beneficial effects of GLP-1 treatment on bone architecture measured by trabecular separation and trabecular bone pattern factor but not BMD or bone volume when compared to normal rats [29] . Micro-CT scans showed higher femoral and vertebral bone mass in 11-week-old hyperlipidaemic rats than in WT rats during treatment with GLP-1 [30] , which was associated with increased mRNA levels of osteoprotegerin and osteocalcin, indicating promotion of bone formation.
Because disruption of the GIP receptor leads to a compensatory increase in GLP-1 secretion and vice versa [31, 32] , GIP À/À and GLP-1R À/À double knockout (DIRKO) mice have been generated. Trabecular bone mass was higher whereas bone diameter and cortical bone mass were lower in 26-weekold DIRKO female mice than in matched WT mice. In addition, several measures of bone mechanical properties including maximal load, hardness and dissipated energy determined by nanoindentation were also impaired in DIRKO mice. Importantly, hyperglycaemia impairs bone formation whereas insulin appears to have bone anabolic properties [9] . Therefore, the increased levels of glucose and decreased levels of insulin in DIRKO mice as observed after an intraperitoneal glucose tolerance test may have contributed to the development of the bone phenotype [33] . The investigation did not include dynamic histomorphometry; therefore, it remains unanswered whether bone formation was different in DIRKO mice. Additionally, GLP-1 may promote collagen maturation as less mature collagen was observed in GLP-1R À/À mice [19] , and combined GLP-1R À/À and GIP À/À mice [33] . Furthermore, GLP-1R is expressed in the calcitonin-secreting C-cells in the murine thyroid gland, and GLP-1 has been shown to promote secretion of calcitonin in rodents [34] . Treatment with calcitonin reduced bone resorption in GLP-1R À/À mice, suggesting that GLP-1 acts on bone through secretion of calcitonin in rodents [20] .
Effects of GLP-1RAs on bone parameters in animals.
Exendin-4. Recently, exendin-4 was shown to increase mouse osteoblastic MC3T3-E1 cell proliferation and the expression of the bone formation markers alkaline phosphatase and osteocalcin together with increased expression of runt-related transcription factor 2, possibly due to increased activity of the MAPK pathway [17] . Feeding 6-week-old Wistar rats with a high-fat diet for 35 days decreased the osteoprotegerin-to-RANKL ratio, increased bone resorption and reduced bone mass [30] . Treating a similar group of high-fat diet rats for 3 days with exendin-4 was associated with a higher osteoprotegerin-to-RANKL ratio, as well as a less pronounced bone loss [30] . Compared to high-fat diet rats, histomorphometry showed that osteoclast number and area of eroded surface and osteoid were lower and bone volume and trabecular thickness substantially greater in high-fat diet rats treated with exendin-4 [30] , suggesting that the GLP-1RA exendin-4 may prevent the deleterious effects of insulin resistance. Treatment of osteoporotic 12-month-old ovariectomized rats for 16 weeks with exendin-4 increased femoral and vertebral BMD dose dependently [35] . A subgroup of these rats were treated with oestradiol and used as positive controls. While estradiol and exendin-4 both reduced the level of bone resorption markers, formation markers osteocalcin and P1NP were higher in rats treated with exendin-4 compared to rats treated with estradiol. Histomorphometric investigations showed that estradiol and exendin-4 increased bone formation rate and mineral apposition rate. Also, the number of osteoblasts was higher in bone tissue from rats treated with exendin-4 compared to estradiol-treated animals. In a comparable study of 12-week-old osteoporotic ovariectomized mice, 4 weeks of treatment with exendin-4 led to increased bone mass as well as trabecular number as assessed by micro-CT and bone histomorphometry [16] . In that study, changes in mineral apposition and bone formation rates were not reported but a decrease in bone resorption was observed [16] .
Effects on osteoclastic bone resorption may be explained by changes in the level of calcitonin, which increased during exendin-4 treatment [16] . Single injections of exendin-4 have been shown to increase calcitonin gene expression [20] , and long-term treatment with exenatide (exendin-4) at high doses increased calcitonin secretion in WT mice but not in GLP-1 À/À mice [34] , further supporting that exenatide may act on bone through promotion of calcitonin secretion in rodents. The ratio of Wnt-pathway activator low-density lipoprotein receptor-related protein 5 to sclerostin increased following 3-day treatment with exendin-4 [29] , and longterm treatment with exendin-4 reduced sclerostin levels in mice [16] , indicating that exendin-4 could increase bone formation.
Liraglutide. In vitro, liraglutide enhanced osteoblast and reduced adipocyte differentiation of rat and human bone marrow stem cells by down-regulating the adipocyte-specific transcription factor PPARc and increasing the expression of runt-related transcription factor 2. Furthermore, expression of collagen-I and alkaline phosphatase was increased, jointly indicating that liraglutide promotes bone formation [36] . Similar to what has been observed with exendin-4 treatment, 4 weeks of treatment with liraglutide prevented trabecular bone loss in 12-week-old ovariectomized mice [16] . Bone histomorphometric analyses revealed no changes in bone formation rate suggesting that liraglutide decreases bone resorption and does not affect bone formation. Changes in calcitonin or sclerostin levels were not reported [16] .
In another study, treatment with liraglutide for 2 months prevented bone loss in 5-month-old ovariectomized rats and increased trabecular bone volume, trabecular thickness and number as well as cortical bone thickness and density despite inducing significant weight loss [36] . Fasting glucose levels were similar in vehicle and liraglutide treated as well as sham-operated rats, demonstrating that glucose-lowering effects of liraglutide cannot account for changes in bone mass. Glucose tolerance, however, was increased by liraglutide treatment, which may have positive effect on bone formation [9] .
The effects of liraglutide on bone metabolism have also been investigated in hyperglycaemic conditions. Treatment of Goto-Kakizaki rats, which develop type 2 diabetes early in life in part due to hypercorticonsteronaemia, for 4 weeks with liraglutide increased both trabecular and cortical bone volume, thickness and density, which was associated with increased expression of the runt-related transcription factor 2, alkaline phosphatase, osteocalcin and collagen type 1 suggesting an anabolic effect on bone [37] . These effects were not observed in study of 8-week-old rats with streptozotocin-induced (insulinopenic) diabetes, where deterioration in cortical bone microarchitecture, lower bone turnover and impaired bone strength were not prevented by treatment with liraglutide for 21 days [28] . Interestingly, microindentation showed that liraglutide improved several tissue material properties, and while collagen maturity and glycation indices were unchanged, liraglutide increased collagen integrity index, suggesting that the drug improved bone strength at tissue level irrespective of coexisting hyperglycaemia [28] .
While GLP-1 appears to promote secretion of calcitonin in rodents, possibly causing the observed changes in bone resorption, long-term treatment of monkeys with very large doses of liraglutide caused neither c-cell hyperplasia nor secretion of calcitonin [34] . These observations highlight that the effects of GLP-1 on bone metabolism may vary substantially between mammals.
Clinical studies.
Clinical studies on incretin hormones and bone metabolism. Few human clinical studies have examined the effects of incretin hormones on bone metabolism. Associations between a GIPR polymorphism known to reduce GIPR activity and lower BMD as well as higher fracture risk were observed in a prospective cohort study comprising perimenopausal women followed for up to 16 years [38] . An intravenous bolus of glucose along with either a single subcutaneous of GLP-1 or an intravenous infusion of GIP in healthy, obese individuals with a mean age of 55 years resulted in non-significant decrease in bone resorption marker collagen type 1 cross-linked C-telopeptide (CTX) with no changes in bone formation marker osteocalcin despite incretin hormone levels exceeding normal postprandial levels by 10 times [39] . By contrast, infusion of GIP at a normal physiological level for one hour reduced bone resorption marker CTX in healthy individuals, and the reduction was higher during hyperglycaemia [40] . Furthermore, during an euglycaemic intravenous glucose infusion neither GIP, GLP-1 nor GLP-2 infusions reduced bone resorption marker CTX as much as an oral glucose tolerance test. However, the combination of GIP, GLP-1 and GLP-2 at physiological doses reduced bone resorption similar to that observed during the oral glucose tolerance test, suggesting that postprandial impairment of bone resorption is explained by combined rather than single effects of incretin hormones on bone remodelling [41] .
Clinical studies and GLP-1RAs. In a 24-week study of patients with type 2 diabetes, no effects of treatment with exenatide (synthetic exendin-4) were observed on either bone turnover markers or BMD [42] . In an open-label, randomized, controlled trial comparing effects of 1.2 mg liraglutide once daily to no treatment in 37 perimenopausal non-diabetic women on diet restriction, significantly lower total body and peripheral bone mineral content (BMC) were observed in the untreated group. Liraglutide increased bone formation markers (P1NP) but not bone resorption markers (CTX) [43] . However, although total hip and lumbar spine BMD were not reported, total and peripheral BMD did not differ between groups. In another 52-week, randomized, double-blind, controlled clinical trial comparing BMD in individuals with type 2 diabetes treated with liraglutide 1.2 mg once daily (n = 20), liraglutide 1.8 mg once daily (n = 23) or glimepiride 8 mg once daily (n = 18), no difference in BMD between groups from baseline to end of the study (104 weeks) was observed [44] .
GLP-1RA had no effect on fracture risk as reported in a meta-analysis, which included a total of 19 fractures identified among six randomized, controlled trials including 4255 individuals treated for a mean duration of 67.4 weeks [45] (table 2). While the I 2 was unreported, the investigators used a random-effects model, possibly indicating heterogeneity between trials. In a more recent meta-analysis based on randomized, controlled clinical trials on liraglutide or exenatide with comparators that included fracture data, lower fracture risk was observed among those treated with liraglutide whereas fracture risk was higher in the exenatide-treated individuals. The analysis was based on 11,206 individuals but only 48 fracture cases [46] (table 2) . Importantly, the investigators did not observe any heterogeneity (I 2 = 0%). In support of these results, a Danish nationwide register-based case-control study comprising more than 200,000 fracture cases and a similar number of controls including 255 users of GLP-1RAs among fracture cases and 220 GLP-1 users in the control group showed that current treatment with a GLP-1RA was not associated with changes in fracture risk. A number of potential confounders such as body mass index and glucose control were not adjusted for in this study, and the mean duration of treatment was only 36 weeks [47] (table 2) .
Discussion
Currently available data suggest that GIP and GLP-1 influence bone metabolism, but the mechanisms have not been established and may comprise both direct and indirect effects as presented in figs 1 and 2. However, the vast majority of the current knowledge of the relationship between GIP, GLP-1 or GLP-1RAs and bone metabolism is based on pre-clinical studies, which have not been confirmed in clinical investigations. Pre-clinical investigations of the effects of GIP on bone metabolism based on activation of the GIPR suggest that GIP inhibits bone resorption. Furthermore, while there is some evidence to suggest that GIP may promote bone formation, the effects of GIP on the quality of the bone matrix remain uncertain. The investigations of effects of GIP on bone metabolism that have been based on GIPR knockout mice have provided contradictory results, showing biochemical and microarchitectural signs of both increased and decreased bone resorption, which may be explained by differences in the methods used to generate and investigate GIPR knockout mice. Thus, the discrepancy between the reports regarding the bone phenotype in GIPR À/À mice could be explained by several factors including variation in age, strain of the mice and nutrition, which are critical for interpretation of the results. Furthermore, deletions of different regions of the extracellular domain of the GIPR [13, 24, 25] may have resulted in dissimilarities of the structure as well as the function of the receptor. It should be acknowledged that the pre-clinical investigations may not reflect effects of GIP on human bone metabolism as interspecies differences between rodents and human GIP receptor ligand and receptor signalling have been reported [48] . Currently available clinical data support that GIP decreases bone resorption in humans as in rodents, but further clinical investigations including treatment of a longer duration and assessment of bone histomorphometry are needed to corroborate these observations. Contrary to GIP, it remains to be established whether GLP-1 or any of the GLP-1 receptor analogues cause changes in rodent and in particular human bone metabolism. Pre-clinical studies based on assessments of GLP-1 receptor inactivation or treatment indicate that GLP-1 promotes bone formation, impairs bone resorption and may promote both bone microstructure and strength, but the mechanisms by which GLP-1 changes these aspects of bone are not clear. Beneficial effects of liraglutide on bone microarchitecture in rats with type 2 diabetes associated with hypercorticosterone but not in an insulinopenic rat model of diabetes could indicate that the effect may depend on insulin levels and insulin sensitivity. While GLP-1 and GLP-1RAs may inhibit bone resorption in rodents by promoting the secretion of calcitonin, studies have consistently shown that GLP-1 and GLP-RAs have no effect on calcitonin secretion in monkeys and humans [34] . This indicates that an indirect pathway between calcitonin stimulation by GLP-1 or GLP-1RAs and beneficial effects on bone remodelling is determined by interspecies differences rather than differences in pharmacokinetics between GLP-1RAs. Therefore, it is unlikely that different GLP-1RAs should have diverging effects on calcitonin in human beings, and a stimulating effect on bone remodelling through a GLP-1 and calcitonin-coupled pathway is not to be expected in human beings.
Glucagon-like peptide-1 may influence proliferation and differentiation of human bone marrow stromal stem cells [21, 23] . Moreover, GLP-1-induced down-regulation of PPARc activity might suggest a commitment of human bone marrow stem cells to osteogenic rather than adipogenic differentiation, ultimately leading to increased bone formation [49] . Along these lines, pre-clinical investigations based on cultured human osteoblasts and osteoclasts including both early stages and fully mature cells indicate that GLP-1 primarily acts on early stages of cell development and may not have any substantial impact on fully developed bone cells. It is currently unknown whether GLP-1 and different GLP-1RAs have similar effects on differentiating and mature bone cells. Based on available pre-clinical data, exendin-4 seems to prevent bone loss, deterioration of bone microstructure and bone strength as observed in conditions known to influence bone remodelling such as postovariectomy, type 2 diabetes and hyperlipidaemia. Pre-clinical studies have also demonstrated that exendin-4 enhances Wnt signalling and possibly bone formation by increasing osteoblast activity and bone formation, possibly by decreasing the levels of sclerostin, which inhibits Wnt signalling. Similarly, liraglutide appears to have anabolic effects on bone remodelling, possibly due to promotion of bone marrow stem cell differentiation towards the osteogenic lineage. Jointly, pre-clinical studies indicate that exendin-4 and liraglutide have similar effects on bone metabolism, implying that other GLP-1RAs are likely to have analogous effects on bone, possibly promoting bone formation and impairing bone resorption.
Clinical investigations of the effects of GLP-1 or different GLP-RAs on the differentiation of bone marrow stem cells as well as osteoblasts, osteoclasts and osteocytes are largely missing, and it also remains to be investigated whether GLP-1 and its analogues influence Wnt signalling or indeed any of the other pathways that are highly involved in the regulation of bone metabolism such as the NF-kB pathway.
Clinical investigations of the effects of GLP1-RAs are limited in number and have not been designed to address the effects of these drugs on bone turnover specifically. Liraglutide was reported to increase the level of a bone formation marker (P1NP) in one intervention study, but the study participants were on a weight-reducing diet, which may have influenced the results. Importantly, the potential promotion of bone formation by liraglutide was not corroborated by increases in BMD at the spine and hip, which would have been anticipated if liraglutide increased bone formation substantially. These observations are in agreement with subgroup investigations of the effect of liraglutide in the LEAD trial and assessments of effects of exanatide on bone turnover and bone mineral density. It should be noted that the available clinical investigations are of short duration, appear not to have been designed to assess effects on bone metabolism as a primary end-point and do not provide in-depth assessments of bone remodelling, that is dynamic histomorphometry of bone biopsies, which limit the possibilities to interpret the results.
Currently available clinical data on effects of GLP-1RAs on human bone metabolism are limited to investigations based on exenatide and liraglutide. The search strategy in the present MiniReview included assessment of publications on presently approved GLP-1RAs and aspects of bone metabolism but not GLP-1RAs that used to be or currently is under investigation, such as taspoglutide and semaglutide. It is not beyond the realms of possibility that these investigational drugs may influence bone metabolism; however, in the interest of space, this MiniReview was focused on marketed GLP-1RAs.
From a clinical perspective, increased fracture risk is the most important outcome of any pharmacologically induced change in bone mass and bone remodelling. Fractures occurring during Fig. 1 . Potential mechanisms of how GIP acts on bone metabolism. Stimulation is illustrated as 'plus' and inhibition as 'minus'. Upward arrows illustrate up-regulation (downward arrows the opposite). GIP appears to act directly on osteoblasts and increase osteoblastic activity resulting in increased bone formation, possibly through cAMP-mediated pathways and through inhibition of osteoblastic apoptosis. GIP may act directly on early stages of mesenchymal stem cells (MSC). GIP may increase secretion of insulin and amylin from pancreatic islets, possibly promoting bone formation.
GLP-1RA treatment have been reported in some but not all intervention studies, and these results have been explored in a number of meta-analyses. Based on available data, GLP-1RAs seem to neither increase nor decrease fracture risk. While further investigations including longer exposure times and adjustment for confounders known to influence fracture risk are desirable, currently available data lend credence to GLP-1RAs as being safe with regard to fracture risk.
Conclusions
Pre-clinical investigations suggest that incretin hormones may have profound effects on bone remodelling and ultimately bone structure and strength. In vitro and in vivo studies in animals suggest that mainly GIP inhibits bone resorption ( fig. 1 ) whereas GLP-1 may promote bone formation, inhibit bone resorption and enhance bone material properties ( fig. 2) . In Figure 2 . Potential mechanisms of how GLP-1 acts on bone metabolism. Stimulation is illustrated as 'plus' and inhibition as 'minus'. Upward arrows illustrate up-regulation (downward arrows the opposite). GLP-1 may act on osteoblasts by (A) increasing osteoprotegerin (OPG)/RANKL ratio thereby inhibiting osteoclast activity resulting in decreased bone resorption and (B) stimulation of GLP-1 on osteoblasts, causing increased levels of the bone formation markers osteocalcin, alkaline phosphatase and collagen a1. GLP-1 acts directly on pancreas, increasing levels of insulin, which acts on osteoblasts to stimulate bone formation. GLP-1 also acts on osteocytes, inhibiting levels of sclerostin, which increases the activity of Wnt pathway resulting in increased osteoblastogenesis and eventually increases bone formation. GLP-1 acts on MSCs and osteoblastogenesis through increasing activity of MAPK pathway, which stimulates osteoblastogenesis resulting in increased bone formation and through decreasing activity of the Protein Kinase C (PKC)-pathway resulting in decreased levels of PPARc, which results in increased activity of osteoblastogenesis and decreased activity of adipogenesis resulting in increased bone formation. In rodents only (grey area), GLP-1 acts on thyroid C-cells, and stimulates secretion of calcitonin, which inhibits osteoclast activity and decreases bone resorption.
humans, GIP might inhibit bone resorption during an intravenous infusion, and the antiresorptive effect appears to be even more pronounced during hyperglycaemia. Exendin-4 and liraglutide appear to be beneficial to bone remodelling, with studies showing mainly antiresorptive effects in animals. By contrast, the effects of incretin hormones and GLP-1RAs in human beings remain elusive. In vitro studies suggest that GLP-1 may increase bone formation in human beings due to effects on osteoprogenitor cell differentiation, but similar studies on effects of GLP-1 as well as GLP-1RAs on mature osteoblastic cells are lacking. Clinical trials designed to test the effect of GLP-1 or GLP-1RAs on bone remodelling have not been conducted. Based on existing albeit sparse data, GIP but not GLP-1 appears to confer alterations to bone remodelling in human beings.
Perspectives
The physiological effects of GIP, GLP-1 and GLP-1RAs on bone metabolism have not been established, and research on the impact of incretin hormones on human osteoblast differentiation and osteoclast activity including their potential interaction with Wnt and NF-kB signalling is needed. Importantly, due to dissimilarities between the expression of GLP-1Rs in animals and human beings, the potential effects of GLP-1RAs on bone cells in vitro and in vivo may differ significantly between pre-clinical and clinical investigations. Several GLPRAs have emerged as antidiabetic drugs, and liraglutide has recently been introduced for the treatment of obesity. Clinical studies assessing bone remodelling during treatment with GLP-1RAs in diabetic due to insulin resistance or insulinopenia, obese and non-diabetic individuals are needed.
